-       Report 
   - August 2024
    -  200 Pages 
    Global
   
   From       €3472EUR$3,869USD£3,047GBP 
                -       Report 
   - May 2023
    -  147 Pages 
    Global
   
   From       €4441EUR$4,949USD£3,898GBP 
                -       Report 
   - August 2024
    -  200 Pages 
    Global
   
   From       €4441EUR$4,949USD£3,898GBP 
                  -       Report 
   - August 2024
    -  150 Pages 
    Global
   
   From       €3455EUR$3,850USD£3,032GBP 
      €4352EUR$4,850USD£3,820GBP 
                -       Report 
   - August 2024
    -  268 Pages 
    Global
   
   From       €3230EUR$3,600USD£2,835GBP 
                 -       Report 
   - June 2022
    -  242 Pages 
    Global
   
   From       €3230EUR$3,600USD£2,835GBP 
                  -       Report 
   - November 2025
     Global
   
   From       €450EUR$537USD£409GBP 
                  -       Report 
   - November 2025
     Global
   
   From       €300EUR$358USD£273GBP 
                -       Report 
   - January 2024
    -  168 Pages 
    Global
   
        €4482EUR$4,995USD£3,934GBP 
                -       Report 
   - January 2024
    -  39 Pages 
    United States
   
             -       Report 
   - January 2024
    -  84 Pages 
    United States
   
             -       Report 
   - May 2023
    -  92 Pages 
     Middle East, Africa, Global Middle East, Africa, Global 
   
   From       €3500EUR$4,178USD£3,179GBP 
                      -       Book 
   - April 2018
    -  248 Pages 
    
                  
         Prostate cancer is a type of cancer that affects the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. It is the most common cancer in men in the United States, and the second most common cause of cancer death in men. Prostate cancer is typically treated with surgery, radiation therapy, hormone therapy, chemotherapy, or a combination of these treatments.
The prostate cancer market within the oncology space is a rapidly growing segment,    driven by the increasing prevalence of the disease and the development of new treatments. The market is expected to benefit from the introduction of novel therapies, such as immunotherapies and targeted therapies, which are expected to improve the prognosis of patients. Additionally, the increasing focus on early diagnosis and the development of new diagnostic tools are expected to drive the market growth.
Some of the key players in the prostate cancer market include AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi. Show Less   Read more